Oral effects of nonmyeloablative stem cell transplantation: A prospective observational study

Quintessence International

Volumn 39, Issue 8, 2008, Pages 673-678

  Elad, Sharon ^a   Shapira, Michael Y ^b   McNeal, Sandre ^c   Or, Reuben ^b   Garfunkel, Adi A ^a   Hirschhorn, Ariel ^a,d   Bitan, Menachem ^b   Resnick, Igor ^b   Benjamin, Gesundheit ^b   Barasch, Andrei ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Israeli Defense Forces ^*

Author keywords

GVHD; Hematopoietic stem cell transplantation; Infection; Myeloablative; Oral

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MOUTH DISEASE; MOUTH MUCOSA; OPPORTUNISTIC INFECTION; PATHOLOGY; PILOT STUDY; PROSPECTIVE STUDY; STEM CELL TRANSPLANTATION;

GRAFT VS HOST DISEASE; MOUTH DISEASES; MOUTH MUCOSA; OPPORTUNISTIC INFECTIONS; PILOT PROJECTS; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 48349139354     PISSN: 00336572     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Resnick IB, Shapira MY, Slavin S. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Transpl Immunol 2005;14:207-219.
2. Slavin S, Aker M, Shapira MY, Resnick I, Bitan M, Or R. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders. Clin Transpl 2003:275-282.
3. Slavin S, Fuks Z, Kaplan HS, Strober S. Transplantation of allogeneic bone marrow without graftversus-host disease using total lymphoid irradiation. J Exp Med 1978;147:963-972.
4. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984;307:168-170.
5. Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplantation tolerance, Immunol Today 1988;9:23-27.
6. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004;10:178-185.
7. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
8. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763.
9. Woo SB, Lee SJ, Schubert MM. Graft-vs.-host disease. Crit Rev Oral Biol Med 1997;8:201-216.
10. Bradley LL, Chambers M, Conklin CE, Fox PC, Garden AS, Haveman CW. Oral health in cancer therapy. A guide for health care professionals [pamphlet]. Dallas: Texas Cancer Council and Academy of General Dentistry Foundations, 2003.
11. Shapira MY, Resnick IB, Bilan M, Ackerstein A, Samuel S, Elad S. Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients. Bone Marrow Transplant 2004;34:155-159.
12. Giralt S. Update on non-myeloablative stem cell transplantation for hematologic malignancies, Int J Hematol 2002;76(suppl 1):368-375.
13. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-758.
14. Weiss L, Slavin S. Prevention and treatment of graftversus-host disease by down-regulation of antihost reactivity with veto cells of host origin. Bone Marrow Transplant 1999;23:1139-1143.
15. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006;12:252-266.